Quick Answer
Corvus Pharmaceuticals, Inc. reported Net Income of -$15.28 million for fiscal year 2025.
Corvus Pharmaceuticals, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$15.28M +75.5% |
-$62.29M -130.5% |
-$27.03M +34.6% |
-$41.31M +4.5% |
-$43.24M -621.3% |
-$6.00M +87.2% |
| Diluted EPS | -$0.53 +48.0% |
-$1.02 -82.1% |
-$0.56 +37.1% |
-$0.89 +13.6% |
-$1.03 -415.0% |
-$0.20 +87.4% |
| Total Assets | $71.12M +3.2% |
$68.91M +51.3% |
$45.55M -33.2% |
$68.24M -37.7% |
$109.45M +28.0% |
$85.53M +2.3% |
| Cash and Equivalents | $4.58M -47.6% |
$8.74M -30.7% |
$12.62M -4.1% |
$13.16M -79.3% |
$63.46M +285.6% |
$16.45M +219.3% |
| Stockholders Equity | $61.20M +87.9% |
$32.57M -15.8% |
$38.68M -31.1% |
$56.12M -42.2% |
$97.16M +34.7% |
$72.15M +1.5% |
| R&D Expense | $33.72M +73.9% |
$19.39M +17.3% |
$16.53M -32.5% |
$24.47M -16.0% |
$29.11M -8.5% |
$31.83M -16.2% |
| Operating Income | -$42.97M -56.0% |
-$27.55M -17.7% |
-$23.41M +28.1% |
-$32.56M +15.7% |
-$38.63M +11.7% |
-$43.76M +10.4% |
| Shares Outstanding | 74.70M +10.0% |
67.90M +38.5% |
49.04M +5.3% |
46.55M +0.0% |
46.55M +64.1% |
28.37M +1.5% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$10.16M | +74.7% | -27.0% |
| Diluted EPS | September 30, 2025 | -$0.12 | +80.0% | -20.0% |
| Total Assets | September 30, 2025 | $80.47M | +36.8% | -10.0% |
| Cash and Equivalents | September 30, 2025 | $2.87M | -38.7% | -80.5% |
| Stockholders Equity | September 30, 2025 | $71.77M | +478.4% | -10.5% |
| R&D Expense | September 30, 2025 | $8.45M | +61.9% | +7.4% |
| Operating Income | September 30, 2025 | -$10.57M | -45.7% | -3.0% |
| Shares Outstanding | September 30, 2025 | 74.68M | +19.3% | +0.2% |
- Corvus Pharmaceuticals, Inc. reported Net Income of -$15.28 million for fiscal year 2025.
- Corvus Pharmaceuticals, Inc. showed an increase of +75.5% in Net Income compared to the prior fiscal year.
- Corvus Pharmaceuticals, Inc. reported Diluted EPS of $0.53 per share (loss) for fiscal year 2025.
- Corvus Pharmaceuticals, Inc. showed an increase of +48.0% in Diluted EPS compared to the prior fiscal year.
- Corvus Pharmaceuticals, Inc. reported Total Assets of $71.12 million for fiscal year 2025.
- Corvus Pharmaceuticals, Inc. showed an increase of +3.2% in Total Assets compared to the prior fiscal year.
- Corvus Pharmaceuticals, Inc. reported Cash and Equivalents of $4.58 million for fiscal year 2025.
- Corvus Pharmaceuticals, Inc. showed a decrease of -47.6% in Cash and Equivalents compared to the prior fiscal year.
- Corvus Pharmaceuticals, Inc. reported Stockholders Equity of $61.20 million for fiscal year 2025.
- Corvus Pharmaceuticals, Inc. showed an increase of +87.9% in Stockholders Equity compared to the prior fiscal year.
- Corvus Pharmaceuticals, Inc. reported R&D Expense of $33.72 million for fiscal year 2025.
- Corvus Pharmaceuticals, Inc. showed an increase of +73.9% in R&D Expense compared to the prior fiscal year.
- Corvus Pharmaceuticals, Inc. reported Operating Income of -$42.97 million for fiscal year 2025.
- Corvus Pharmaceuticals, Inc. showed a decrease of -56.0% in Operating Income compared to the prior fiscal year.
- Corvus Pharmaceuticals, Inc. reported Shares Outstanding of 74.70 million shares for fiscal year 2025.
- Corvus Pharmaceuticals, Inc. showed an increase of +10.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: